Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages 60-65

  Seiler, Milton ^a   Ray Coquard, Isabelle ^b   Melichar, Bohuslav ^c   Yardley, Denise A ^d   Wang, Rui X ^e   Dodion, Pierre F ^f   Lee, Mark A ^g  

^a Hematology and Oncology Specialists LLC Harry T Howard II Memorial Infusion Center   (United States)

^b HÔpital d'instruction des armées Desgenettes   (France)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e R and D China Co Ltd   (China)

^f ARIAD PHARMACEUTICALS INC   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Breast cancer; HER2; mTOR inhibitor; Ridaforolimus; Trastuzumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RIDAFOROLIMUS; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RAPAMYCIN;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANUS DISEASE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BODY WEIGHT DISORDER; BREAST METASTASIS; CANCER RESISTANCE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INTESTINE PERFORATION; LEUKOPENIA; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRURITUS; RASH; SORE THROAT; STOMATITIS; THROMBOCYTOPENIA; TONGUE SWELLING; TREATMENT OUTCOME; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 84920276580     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.07.008     Document Type: Article

References (26)

1. F.F. Barros, D.G. Powe, and I.O. Ellis Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments Histopathology 56 2010 560 572
2. D. Yu, and M.C. Hung Overexpression of ErbB2 in cancer and ErbB2-targeting strategies Oncogene 19 2000 6115 6121
3. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
4. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
5. K. Berns, H.M. Horlings, and B.T. Hennessy A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 2007 395 402
6. Y. Nagata, K.H. Lan, and X. Zhou PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127
7. T.T. Junttila, R.W. Akita, and K. Parsons Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 Cancer Cell 15 2009 429 440
8. Q.B. She, S. Chandarlapaty, and Q. Ye Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling PLoS One 3 2008 e3065
9. V.M. Rivera, R.M. Squillace, and D. Miller Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens Mol Cancer Ther 10 2011 1059 1071
10. R.M. Squillace, D. Miller, and M. Cookson Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models Mol Cancer Ther 10 2011 1959 1968
11. S.P. Chawla, A.P. Staddon, and L.H. Baker Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas J Clin Oncol 30 2012 78 84
12. G.D. Demetri, S.P. Chawla, and I. Ray-Coquard Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy J Clin Oncol 31 2013 2485 2492
13. M.M. Mita, E. Poplin, and C.D. Britten Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma Ann Oncol 24 2013 1104 1111
14. J. Baselga, D. Tripathy, and J. Mendelsohn Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
15. M.A. Cobleigh, C.L. Vogel, and D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648
16. G. von Minckwitz, A. du Bois, and M. Schmidt Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 2009 1999 2006
17. C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
18. S. Verma, D. Miles, and L. Gianni Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 2012 1783 1791
19. H.S. Han, C. Swanton, and Y.Y. Janjigian A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors J Clin Oncol 29 2011 abstract 3028
20. S. Vinayak, and R.W. Carlson mTOR inhibitors in the treatment of breast cancer Oncology (Williston Park) 27 2013 38 48
21. J. Baselga, M. Campone, and M. Piccart Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
22. F. Andre, M. Campone, and R. O'Regan Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab J Clin Oncol 28 2010 5110 5115
23. G. Jerusalem, A. Fasolo, and V. Dieras Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer Breast Cancer Res Treat 125 2011 447 455
24. F. Andre, R. O'Regan, and M. Ozguroglu Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Lancet Oncol 15 2014 580 591
25. I.E. Krop, C. Saura, and J.R. Ahnert A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer J Clin Oncol 30 suppl 2012 abstract 508
26. P.K. Morrow, G.M. Wulf, and J. Ensor Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy J Clin Oncol 29 2011 3126 3132